+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Novel monoclonal antibodies for chronic lymphocytic leukemia - ofatumumab, alemtuzumab



Novel monoclonal antibodies for chronic lymphocytic leukemia - ofatumumab, alemtuzumab



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(5): 558-562




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058433207

Download citation: RISBibTeXText

PMID: 26054090


Related references

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leukemia and Lymphoma 60(5): 1312-1315, 2019

Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. Therapeutic Advances in Hematology 7(4): 222-230, 2016

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. American Journal of Hematology 87(12): E133, 2012

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clinical Cancer Research 16(17): 4331-4338, 2010

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clinical Lymphoma Myeloma and Leukemia 10(5): 361-368, 2010

Ofatumumab A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia. Current Drug Therapy 7(4): 281-289, 2012

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 11: Cd008079, 2012

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Annals of PharmacoTherapy 45(10): 1248-1255, 2011

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncology 9(12): 1829-1839, 2013

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica 100(4): 511-516, 2015

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology 3(4): 199-207, 2012

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technology Assessment 15(Suppl. 1): 61-67, 2011

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111(3): 1094-1100, 2008

Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia and Lymphoma 56(4): 915-920, 2015

The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist 15(12): 1335-1343, 2010